Document Type
Article
Publication Date
6-2024
Identifier
DOI: 10.1016/j.isci.2024.109975; PMCID: PMC11140213
Abstract
Severe COVID-19 often leads to secondary infections and sepsis that contribute to long hospital stays and mortality. However, our understanding of the precise immune mechanisms driving severe complications after SARS-CoV-2 infection remains incompletely understood. Here, we provide evidence that the SARS-CoV-2 envelope (E) protein initiates innate immune inflammation, via toll-like receptor 2 signaling, and establishes a sustained state of innate immune tolerance following initial activation. Monocytes in this tolerant state exhibit reduced responsiveness to secondary stimuli, releasing lower levels of cytokines and chemokines. Mice exposed to E protein before secondary lipopolysaccharide challenge show diminished pro-inflammatory cytokine expression in the lung, indicating that E protein drives this tolerant state in vivo. These findings highlight the potential of the SARS-CoV-2 E protein to induce innate immune tolerance, contributing to long-term immune dysfunction that could lead to susceptibility to subsequent infections, and uncovers therapeutic targets aimed at restoring immune function following SARS-CoV-2 infection.
Journal Title
iScience
Volume
27
Issue
6
First Page
109975
Last Page
109975
Keywords
components of the immune system; immunity; molecular biology; transcriptomics; virology
Recommended Citation
Geanes ES, McLennan R, Pierce SH, et al. SARS-CoV-2 envelope protein regulates innate immune tolerance. iScience. 2024;27(6):109975. Published 2024 May 15. doi:10.1016/j.isci.2024.109975
Comments
This article is available under the Creative Commons CC-BY-NC-ND license and permits non-commercial use of the work as published, without adaptation or alteration provided the work is fully attributed.
Publisher's Link: https://doi.org/10.1016/j.isci.2024.109975